BUSINESS/FINANCE NEWS
Setup News Ticker
   BUSINESS/FINANCE NEWS
Searching for 'Stock investors'. (Return)

MarketWatchOct 24, 2020
Market Extra: Stock-market investors brace for busiest week of earnings in October's final hurrah
The S&P 500's tech giants will vie for attention as they barrage the market with third-quarter earnings in the week before the Nov. 3 election.

RELATED ARTICLES
FA Center: ‘Trump stocks' have significantly lagged the U.S. market since 2016 — while ‘Clinton stocks' have soared (MarketWatch)

MarketWatchOct 24, 2020
NewsWatch: Stock-market investors brace for busiest week of earnings in October's final hurrah
The S&P 500's tech giants will vie for attention as they barrage the market with third-quarter earnings in the week before the Nov. 3 election.

MarketWatch MarketPulseOct 21, 2020
Biogen's earnings tumble 55% in the third quarter of 2020
Shares of Biogen were down 0.1% in premarket trading on Wednesday after the company missed earnings expectations for the quarter. The drug maker had earnings of $701.50, or $4.46 per share, in the third quarter of 2020, a 55% decline in earnings compared with the $1,545.90, or $8.39 per share, it reported in the same quarter a year ago. Adjusted earnings per share were $4.47 for the quarter, against a FactSet consensus of $8.03. Biogen reported revenue of $3.37 billion for the quarter, a 6% decline from the $3.60 billion it reported in the third quarter of last year. The FactSet consensus was $3.33 billion. The company cited a quarterly drop in sales of some of its multiple sclerosis drugs, including the company's flagship product, Tecfidera, which had revenue of $968 million in the third quarter, compared with $1.12 billion in the same quarter in 2019. Sales of the spinal muscular atrophy drug Spinraza also tumbled, by 10% to $495 million. However, revenue in its smaller biosimilars business was up for the quarter, led by a 7% increase in sales to $124 million of rheumatoid arthritis drug Benepali. Investors are preparing for an upcoming Food and Drug Administration advisory committee meeting for its experimental and somewhat controversial Alzheimer's disease drug aducanumab. The meeting is expected to be held Nov. 6. Biogen cut its guidance for revenue and adjusted EPS for the year, saying it now expects $13.2 billion to $13.4 billion in revenue for the year, compared with its previous guidance of $13.8 billion to $14.2 billion for 2020. It now expects adjusted EPS of $32.50 to $33.50 for the year, compared with previous guidance of $34.00 to $36.00. Biogen's stock is down 10.0% for the year, while the S&P 500 is up 6.5%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.


TRENDING TAGS
Coronaviruspositive cases Pence tests CNN
Covid-19cases Utah update NBC Saturday
TrumpBiden Washington Post states stops
reporting
StockBuy Market investors Biden Election
BidenTrump states Florida rally Obama
Stimuluscheck
StocksBuy These Right Buys Wins
BusinessInsider Biden crass attack political
SamsungLee Kun-hee Dies Chairman titan

NEWS SOURCES
Top News (Business News)
Accounting Today
AdWeek News
Banking Business Review
Barron's This Week Magazine
Barron's Up and Down Wall Street Daily
Brad Ideas
Chicago Tribune Business News
CNBC Business
CNBC Economy
CNBC Finance
CNN/Money
CNN/Money Real Estate News
Dismal.com: Analysis
Dismal.com: Indicators
Enterprise Application News
Entrepreneur.com
Forbes Headlines
Forbes Social Media News
FT.com - China, Economy & Trade
FT.com - Financial Markets
FT.com - Hedge Funds
FT.com - Telecoms
FT.com - US
Google Business News
Google Market News
HBS Working Knowledge
Inc.com
INSEAD Knowledge
International Tax Review
Kiplinger
Knowledge@Wharton
L.S. Starrett News
MarketWatch
MarketWatch Breaking News
MarketWatch MarketPulse
McKinsey Quarterly
MSNBC.com: Business
Nielsen Trends
NonProfit Times
NPR Topics: Business
NYTimes Business
OpinionJournal.com
Private Equity Breaking News
Reuters Business
Reuters Company News
Reuters Money
SEC.gov Updates: News Digest
SHRM HR News
Tax Policy News
The Economist International News
The Motley Fool
USA Today Money
Wall Street Journal US Business
Wall Street Transcript
Washington Post Business
WSJ Asia
WSJ Europe
WSJ MoneyBeat
WSJ Opinion
WSJ US News
WSJ World Markets
Yahoo Business
  • CEOExpress
  • 1 Boston Place | Suite 2600
    Boston MA 02108
  • 617 482 1200
    617 299 8649 (fax)
  • Contact
  • As an Amazon Associate
    CEOExpress earns from
    qualifying purchases.

©1999-2020 CEOExpress Company LLC